Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Liver Tumors
How does the use of checkpoint inhibitors for treatment of HCC impact timing of liver transplant and subsequent immunosuppression?
Related Questions
What pre-transplant patient factors impact surveillance intervals and methods after liver transplant for HCC?
How does your surveillance and management approach differ between intra-hepatic and extra-hepatic cholangiocarcinoma?
What patient factors impact your selection of initial therapies in patients with localized cholangiocarcinoma?
How has the GALAD score affected your practice for HCC screening?
How do you foresee the integration of artificial intelligence in the management and evaluation of patients with liver lesions/tumors?
How does the identification of a hepatic adenoma in a male patient affect your management and evaluation?
What is your evaluation approach for a new patient referral for an incidentally found liver lesion?
How do you approach treatment options for patients with fibrolamellar HCC compared to "normal" HCC?
When would you plan to biopsy a hepatic adenoma to see if it has high risk features/mutations?
How do you approach a conversation with a patient with a markedly positive PETH (>200 ug/L) who is insistent that they do not consume any alcohol?
